Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study

Autor: Morten Kranker Larsen, Vibe Skov, Lasse Kjær, Christina Schjellerup Eickhardt-Dalbøge, Trine Alma Knudsen, Marie Hvelplund Kristiansen, Anders Lindholm Sørensen, Troels Wienecke, Morten Andersen, Johnny T. Ottesen, Johanne Gudmand-Høyer, Jordan Andrew Snyder, Mikkel Porsborg Andersen, Christian Torp-Pedersen, Henrik Enghusen Poulsen, Thomas Stiehl, Hans Carl Hasselbalch, Christina Ellervik

Publikováno v: Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)

Abstract The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population

Externí odkaz: https://doaj.org/article/46ca4a43de774498aff8a1da1a776787

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia

Autor: Christina Schjellerup Eickhardt-Dalbøge, Anna Cäcilia Ingham, Henrik V. Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O'Brien Andersen, Morten Kranker Larsen, Lasse Kjær, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Christina Ellervik, Lars Rønn Olsen, Hans Carl Hasselbalch, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen

Publikováno v: Microbiology Spectrum, Vol 11, Iss 5 (2023)

ABSTRACT Essential thrombocythemia (ET) is part of the Philadelphia chromosome-negative myeloproliferative neoplasms. It is characterized by an increased risk of thromboembolic events and also to a certain degree hypermetabolic symptoms. The gut micr

Externí odkaz: https://doaj.org/article/b3609417a5e84dac83bf1109859a4035

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis

Autor: Lasse Kjær, Vibe Skov, Morten Kranker Larsen, Tobias Idor Boklund, Morten Andersen, Maria Kefala, Trine A. Knudsen, Christina Schjellerup Eickhardt-Dalbøge, Thomas Stiehl, Johanne Gudmand-Høyer, Jordan Snyder, Morten Holmström, Mads H. Andersen, Johnny T. Ottesen, Christina Ellervik, Hans C. Hasselbalch

Publikováno v: Frontiers in Oncology, Vol 13 (2023)

Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocy

Externí odkaz: https://doaj.org/article/ee792f216b2a41bf8a7c41cd3ed8d0cd

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives

Autor: Hans Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine A. Knudsen, Marko Lucijanić, Rajko Kusec

Publikováno v: Hasselbalch, H, Skov, V, Kjær, L, Larsen, M K, Knudsen, T A, Lucijanić, M & Kusec, R 2022, ' Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms : Rationales and Perspectives ', Cancers, vol. 14, no. 22, 5495 . https://doi.org/10.3390/cancers14225495

About 30 years ago, the first clinical trials of the safety and efficacy of recombinant interferon-α2 (rIFN-α2) were performed. Since then, several single-arm studies have shown rIFN-α2 to be a highly potent anticancer agent against several cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94e258cfc9d162198bbbfc8aad765df6
https://pubmed.ncbi.nlm.nih.gov/36428587

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2

Autor: Marc J. B. Dam, Rasmus K. Pedersen, Trine A. Knudsen, Morten Andersen, Christina Ellervik, Morten Kranker Larsen, Lasse Kjær, Vibe Skov, Hans C. Hasselbalch, Johnny T. Ottesen

Publikováno v: Dam, M J B, Pedersen, R K, Knudsen, T A, Andersen, M, Ellervik, C, Larsen, M K, Kjær, L, Skov, V, Hasselbalch, H C & Ottesen, J T 2023, ' A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2 ', Cancer Medicine, vol. 12, no. 4, pp. 4218-4226 . https://doi.org/10.1002/cam4.5285

Background: Conventional cytoreductive therapy for patients with chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon-alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4458ec9bc99abde5d99b50ca2df51200
https://pubmed.ncbi.nlm.nih.gov/36254099